ACR 2020: Investigational Deucravacitinib Shows Promise in Difficult-to-Treat Psoriatic Arthritis
The drug works via a novel tyrosine kinase-inhibiting mechanism
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.